Can AI outperform doctors? Insilico Medicine, Biocon CEOs weigh in
Özlem | An | Getty Images
You may already be familiar with AI being used in your doctor’s office to help take notes or schedule appointments or analyze medical images.
But some experts believe consumers should use AI even more to help them understand their health.
“People should be using AI much more than they do today,” according to Alex Zhavoronkov, founder and CEO of an AI drug discovery company. Insilico Medicine.
“Many of the AI models used by consumers actually achieve a level of capability close to, and sometimes better than, that of some doctors,” Zhavoronkov told a panel at CNBC’s CONVERGE LIVE event in Singapore on Wednesday. he said.
“What should I eat? … Should I go on a diet?” He advocated the use of artificial intelligence to answer basic health questions such as. he said. “Some very basic questions can be answered for you by an AI doctor, you will actually save time with a real doctor,” he added.
ChatGPT and Amazon launch health tools
Artificial intelligence is being used in consumer healthcare in a variety of ways.
Shreehas Tambe, CEO and managing director of the biotechnology company bioconeHe said he was cautiously optimistic about the use of AI in healthcare settings, describing a “learning curve” for new users.
“I think trying to put an advanced technology platform in the hands of someone who is probably still getting used to it can lead to more inaccurate results,” he told CONVERGE LIVE.
“Then you may encounter more challenges than benefits of this technology,” Tambe added.
AI tools have reduced the research time for drugs to reach the developmental candidate stage to 18 months, compared to the traditionally more than four years, Zhavoronkov said. Developmental candidates are part of the drug discovery process that occurs before human trials. Pharmaceutical giant in March Eli Lilly It signed a $2.75 billion deal with Insilico Medicine to bring to market drugs developed using AI.
Validating AI models used in the discovery of new drugs is important for the “human in the loop,” Tambe said. “You need these models to be validated by people who understand the science, who can push the boundaries and say this is the solution I want these generative models to develop,” he said.
— CNBC’s Ashley Capoot and Annie Palmer contributed to this report.
